Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 7;13:7851–7864. doi: 10.2147/OTT.S253485

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

The expression of MCT1 and LDHB, and the plasma IL-6 level in CRLM was elevated in irinotecan-resistant patients. (A) IHC was used to analyze MCT1 and LDHB in the liver metastases of irinotecan-sensitive and irinotecan-resistant patients. (B) ELISA was used to detect the concentration of IL-6 in the plasma of patients with PD (n=39) and SD or PR (n=39). (C–E) The correlation between the plasma IL-6 concentration and the level of CA199, the extrahepatic metastases state, and the number of liver metastases.